Commentary

Video

Contralateral Breast Cancer Treatment With Germline Mutation Carriers

Siddartha Yadav, MD, FACP, of Mayo Clinic, discusses personalizing treatment for patients with germline–mutant contralateral breast cancer.

Siddartha Yadav, MD, FACP, assistant professor of oncology, senior associate consultant, Womens Oncology Program, at Mayo Clinic, discusses how to personalize treatment for patients with contralateral breast cancer, specifically in those with germline mutations.

Yadav's research is primarily focused on identifying genes and variants involved in susceptibility to cancers of the breast, ovaries, pancreas, and prostate using genetic epigenomics, epidemiologic, and functional studies, as well as characterizing the molecular biology and clinical outcomes of tumors with germline mutations in DNA repair genes.

"I believe [it] is very important because, you know, we can't just treat everybody the same, right? Because everybody is different and if you have a germline mutation that led to the breast or ovarian cancer, we know that those tumors are different compared to your regular breast or ovarian cancer," Yadav said. "I'm very proud and I feel privileged to be able to take care of these 5% to 10% of patients."

Yadav was motivated to conduct a study on contralateral breast cancer in patients with some of the germline mutations beyond BRCA1/2 and the risk of developing a second breast cancer.

"We know that [patients with] BRCA1/2, if they have first breast cancer, they are still at risk of developing second breast cancer and often will undergo bilateral mastectomies because of that. But that may not apply to ATM, CHEK2, PALB2, and people didn't just have data," Yadav explained in the interview. "You will hear from communities that a lot of women who are ATM, CHEK2, or PALB2 [positive] were undergoing bilateral mastectomy just because of that. And the lack of data, again, this goes to this whole concept of personalized medicine, right? If you don't have data, you can't really offer personalized medicine because now you can't tell these women what is your risk."

Related Videos
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Margaret E. Gatti-Mays, MD, MPH, FACP
Justin Kaner, MD